Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2020 1
2021 1
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

4 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Refractory Diffuse Intrinsic Pontine Glioma"
Page 1
Immunotherapy approaches for the treatment of diffuse midline gliomas.
Bernstock JD, Hoffman SE, Kappel AD, Valdes PA, Essayed W, Klinger NV, Kang KD, Totsch SK, Olsen HE, Schlappi CW, Filipski K, Gessler FA, Baird L, Filbin MG, Hashizume R, Becher OJ, Friedman GK. Bernstock JD, et al. Oncoimmunology. 2022 Sep 26;11(1):2124058. doi: 10.1080/2162402X.2022.2124058. eCollection 2022. Oncoimmunology. 2022. PMID: 36185807 Free PMC article. Review.
Diffuse midline gliomas (DMG) are a highly aggressive and universally fatal subgroup of pediatric tumors responsible for the majority of childhood brain tumor deaths. ...We explore the use of cell-based therapies, oncolytic virotherapy or immunovirotherapy, immune checkpoi …
Diffuse midline gliomas (DMG) are a highly aggressive and universally fatal subgroup of pediatric tumors responsible for the majority …
Nimotuzumab therapy in the treatment of pediatric central nervous system tumors: single-center experience.
Susam-Sen H, Varan A, Bajin İ, Göçmen R, Aydın B, Yalcin B, Kurucu N, Kutluk T, Bayhan T, Akyuz C. Susam-Sen H, et al. Naunyn Schmiedebergs Arch Pharmacol. 2021 Aug;394(8):1769-1777. doi: 10.1007/s00210-021-02109-y. Epub 2021 Jun 21. Naunyn Schmiedebergs Arch Pharmacol. 2021. PMID: 34151393
Relapsed or refractory central nervous system (CNS) tumors still have poor prognosis, and, therefore, new treatment options are required. We retrospectively researched treatment results of patients with CNS tumors treated with nimotuzumab from 2010 to 2015. The stud …
Relapsed or refractory central nervous system (CNS) tumors still have poor prognosis, and, therefore, new treatment options ar …
Immune checkpoint inhibition for pediatric patients with recurrent/refractory CNS tumors: a single institution experience.
Cacciotti C, Choi J, Alexandrescu S, Zimmerman MA, Cooney TM, Chordas C, Clymer J, Chi S, Yeo KK. Cacciotti C, et al. J Neurooncol. 2020 Aug;149(1):113-122. doi: 10.1007/s11060-020-03578-6. Epub 2020 Jul 5. J Neurooncol. 2020. PMID: 32627129 Clinical Trial.
We describe our experience with immune checkpoint inhibition in recurrent/refractory pediatric CNS tumors. METHODS: We performed a retrospective chart review of pediatric patients with recurrent or refractory CNS tumors treated with ipilimumab, nivolumab and/or pemb …
We describe our experience with immune checkpoint inhibition in recurrent/refractory pediatric CNS tumors. METHODS: We performed a re …
Phase I study of bevacizumab plus irinotecan in pediatric patients with recurrent/refractory solid tumors.
Okada K, Yamasaki K, Tanaka C, Fujisaki H, Osugi Y, Hara J. Okada K, et al. Jpn J Clin Oncol. 2013 Nov;43(11):1073-9. doi: 10.1093/jjco/hyt124. Epub 2013 Sep 3. Jpn J Clin Oncol. 2013. PMID: 24002900 Clinical Trial.
The dose of irinotecan was 340 mg/m(2) for patients receiving enzyme-inducing antiepileptic drugs. Treatment was repeated every 6 weeks for up to three courses in the absence of disease progression or unacceptable toxicity. ...The most frequent non-dose-limiting toxicities …
The dose of irinotecan was 340 mg/m(2) for patients receiving enzyme-inducing antiepileptic drugs. Treatment was repeated every 6 weeks for …